Education
About Us
Working with TipRanks
Follow Us
Genmab (Otc) (GMAB)
:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.24 - $33.63
Previous CloseN/A
Volume229.76K
Average Volume (3M)2.08M
Market Cap
$19.59B
Enterprise Value$9.96B
Total Cash (Recent Filing)$18.37B
Total Debt (Recent Filing)$937.88M
Price to Earnings (P/E)15.8
Beta0.53
Next Earnings
Nov 06, 2025EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding642,063,500
10 Day Avg. Volume3,360,244
30 Day Avg. Volume2,081,926
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda1.30
Forecast
1Y Price Target
$39.60Price Target Upside24.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsThe acquisition of Merus accelerates Genmab's shift from a royalty to a wholly owned model with long-term growth potential.
Market OpportunityPetosemtamab's market opportunity in head and neck cancer alone could exceed $3B annually.
Pipeline GrowthGenmab's late-stage pipeline has the potential for over $8 billion in annual revenue, bolstered by promising assets like Epkinly and Rina-S.
Bears Say
Debt ConcernsConcerns exist regarding the debt required to complete the Merus acquisition, influencing the current flat trading of Genmab shares.
Financial BurdenThe $8B deal is sizable and carries significant operating expenses and interest expense dilution in the initial years following the acquisition.
Genmab News
GMAB FAQ
What was Genmab (Otc)’s price range in the past 12 months?
Genmab (Otc) lowest stock price was $17.23 and its highest was $33.63 in the past 12 months.
What is Genmab (Otc)’s market cap?
Genmab (Otc)’s market cap is $19.59B.
When is Genmab (Otc)’s upcoming earnings report date?
Genmab (Otc)’s upcoming earnings report date is Nov 06, 2025 which is in 24 days.
How were Genmab (Otc)’s earnings last quarter?
Genmab (Otc) released its earnings results on Aug 07, 2025. The company reported $0.542 earnings per share for the quarter, beating the consensus estimate of $0.399 by $0.143.
Is Genmab (Otc) overvalued?
According to Wall Street analysts Genmab (Otc)’s price is currently Undervalued.
Does Genmab (Otc) pay dividends?
Genmab (Otc) does not currently pay dividends.
What is Genmab (Otc)’s EPS estimate?
Genmab (Otc)’s EPS estimate is 0.47.
How many shares outstanding does Genmab (Otc) have?
Genmab (Otc) has 642,063,500 shares outstanding.
What happened to Genmab (Otc)’s price movement after its last earnings report?
Genmab (Otc) reported an EPS of $0.542 in its last earnings report, beating expectations of $0.399. Following the earnings report the stock price went up 5.486%.
Which hedge fund is a major shareholder of Genmab (Otc)?
Currently, no hedge funds are holding shares in GMAB
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.60 (24.49% Upside)
$39.60 (24.49% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 425.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.6%
Last 30 Days ▲ 27.2%
Last 30 Days ▲ 27.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.16%
12-Months-Change
Fundamentals
Return on Equity
26.08%
Trailing 12-Months
Asset Growth
16.47%
Trailing 12-Months
Company Description
Genmab (Otc)
Genmab (GMAB) is a leading international biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on creating innovative treatments that harness the body's immune system to combat malignancies. The company is known for its proprietary technologies, such as the DuoBody platform, which enables the development of bispecific antibodies, and has a robust pipeline of product candidates, including its flagship drug, Darzalex (daratumumab), used in multiple myeloma treatment.
GMAB Company Deck
GMAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$39.60
▲(24.49% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.89% Mutual Funds
2.96% Other Institutional Investors
95.34% Public Companies and Individual Investors